☆ 4.6 Article

Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)

DIAGNOSTICS (2023)

Related references

Note: Only part of the references are listed.

Review Medicine, General & Internal

Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review

Arianna Zappi et al.

Summary: Neuroendocrine tumors (NETs) have diverse clinical behaviors, ranging from long survival in well-differentiated NETs to poor prognosis in high-grade neuroendocrine carcinomas (NECs). The use of chemotherapy in NECs is well established, but data on NETs is limited and mainly derived from small studies and expert opinions. This review aims to summarize the available evidence on chemotherapy in G1-2 NETs and G3 NETs. While specific treatment regimens have shown efficacy in gastroenteropancreatic NETs (GEP-NETs) and thoracic NETs, solid evidence on the efficacy of chemotherapy in G3 NETs is still lacking. Further studies are needed to better understand the role of chemotherapy in this setting.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Oncology

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

Pamela T. Kunz et al.

Summary: In patients with advanced pancreatic neuroendocrine tumors (NETs), the combination of capecitabine and temozolomide showed significant improvement in progression-free survival compared to temozolomide alone. This combination therapy achieved the highest reported median progression-free survival and response rate in a randomized study for pancreatic NETs.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System

Shinichi Yachida et al.

Summary: Gastrointestinal neuroendocrine carcinoma (GIS-NEC) is a rare but highly malignant tumor that is genetically distinct from gastrointestinal neuroendocrine tumors (GIS-NET). There are clear genomic differences between pancreatic NECs (Pant-NEC) and nonpancreatic GIS-NECs (Nonpanc-NEC). Panc-NECs can be classified into two subgroups based on genomic and epigenomic features.

CANCER DISCOVERY (2022)

Add to Collection

Article Endocrinology & Metabolism

A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study

Wei Wang et al.

Summary: The study investigated the clinical utility of Ki-67 index in predicting the response to the CAPTEM regimen in metastatic NENs patients. Patients with Ki-67 range of 10-40% demonstrated higher response rates to the CAPTEM regimen. Ki-67 index was identified as an important prognostic factor for overall survival and progression-free survival in patients treated with the CAPTEM regimen.

NEUROENDOCRINOLOGY (2021)

Add to Collection

Article Cell Biology

Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours

Kris G. Samsom et al.

Summary: The study revealed that driver mutations occur in 50% of metastatic SI-NETs, and their presence is associated with a high Ki67 proliferation index. Potential targetable genetic alterations were commonly detected in metastatic SI-NETs.

HISTOPATHOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations

Hege Elvebakken et al.

Summary: In this study, high-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) were classified based on morphology and proliferation rate, leading to the differentiation of well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Specific morphological criteria such as organoid growth pattern, capillary network contact to tumor cells, and absence of desmoplastic stroma were found to be useful in distinguishing between the two types. Patients stratified by morphology and proliferation rate showed significant differences in response to chemotherapy and overall survival, highlighting the importance of accurate classification in guiding treatment decisions for high-grade GEP-NENs.

NEUROENDOCRINOLOGY (2021)

Add to Collection

Article Oncology

Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

Marianne Pavel et al.

Summary: Reducing the dosing interval of lanreotide autogel to every 14 days in patients with progressive NETs following standard-regimen LAN showed encouraging progression-free survival, especially in patients with a Ki-67 < 10%; there were no safety concerns and no deterioration in quality of life.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Endocrinology & Metabolism

Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A Real-World Data Analysis

Alberto Bongiovanni et al.

Summary: TEM-based regimens show a high disease control rate and relatively tolerable toxicity profile in NENs of pancreatic, intestinal, and lung origin. Further investigation of these specific NETs is warranted in prospective clinical trials.

NEUROENDOCRINOLOGY (2021)

Add to Collection

Article Oncology

Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide

Taymeyah Al-Toubah et al.

Summary: This study demonstrated that FOLFOX chemotherapy has activity in aggressive pNETs that have progressed after prior cap/tem treatment, but the durations of response are relatively short, highlighting the need for new and more effective treatment options for patients with aggressive transformation of pancreatic NETs.

ONCOLOGIST (2021)

Add to Collection

Review Oncology

Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials

Claudio Ricci et al.

Summary: SSAs alone remain the best choice for treating well-differentiated GEP-NENs, while Lu-177-Dotatate plus SSA is a valid alternative for midgut NENs.

CANCERS (2021)

Add to Collection

Article Multidisciplinary Sciences

Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas

Sun Mi Lee et al.

Summary: Poorly differentiated neuroendocrine carcinoma (NEC) of the colorectum is a rare subtype of colorectal cancer with poor prognosis and high rates of metastasis, showing high frequencies of BRAF and RB1 mutations.

SCIENTIFIC REPORTS (2021)

Add to Collection

Editorial Material Cell Biology

The 2019 WHO classification of tumours of the digestive system

Iris D. Nagtegaal et al.

HISTOPATHOLOGY (2020)

Add to Collection

Article Endocrinology & Metabolism

Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor

Giuseppe Lamberti et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)

Add to Collection

Article Oncology

Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

Alberto Puccini et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms

Elettra Merola et al.

PANCREAS (2020)

Add to Collection

Article Pathology

Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets

Ha Young Park et al.

HUMAN PATHOLOGY (2019)

Add to Collection

Article Endocrinology & Metabolism

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses

Louis de Mestier et al.

NEUROENDOCRINOLOGY (2019)

Add to Collection

Article Oncology

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials

James Yao et al.

ENDOCRINE-RELATED CANCER (2019)

Add to Collection

Article Oncology

Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma

Kamran Idrees et al.

JOURNAL OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Biochemistry & Molecular Biology

ClinVar: improving access to variant interpretations and supporting evidence

Melissa J. Landrum et al.

NUCLEIC ACIDS RESEARCH (2018)

Add to Collection

Article Endocrinology & Metabolism

Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study

Davide Campana et al.

ENDOCRINE (2018)

Add to Collection

Article Oncology

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis

Nicola Fazio et al.

CANCER SCIENCE (2018)

Add to Collection

Article Multidisciplinary Sciences

Whole-genome landscape of pancreatic neuroendocrine tumours

Aldo Scarpa et al.

NATURE (2017)

Add to Collection

Article Gastroenterology & Hepatology

O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors

Nitya Raj et al.

PANCREAS (2017)

Add to Collection

Article Oncology

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Oncology

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Martyn E. Caplin et al.

ENDOCRINE-RELATED CANCER (2016)

Add to Collection

Article Oncology

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study

James C. Yao et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Endocrinology & Metabolism

Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors

Francesca Spada et al.

NEUROENDOCRINOLOGY (2016)

Add to Collection

Article Endocrinology & Metabolism

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

M. Pavel et al.

NEUROENDOCRINOLOGY (2016)

Add to Collection

Meeting Abstract Oncology

Capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NEN): An Italian multicenter retrospective analysis

Francesca Spada et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Meeting Abstract Oncology

Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors

Robert Lance Fine et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Mathematical & Computational Biology

Joint confidence region estimation for area under ROC curve and Youden index

Jingjing Yin et al.

STATISTICS IN MEDICINE (2014)

Add to Collection

Article Oncology

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

H. Sorbye et al.

ANNALS OF ONCOLOGY (2013)

Add to Collection

Article Endocrinology & Metabolism

Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series

Vita Saranga-Perry et al.

NEUROENDOCRINOLOGY (2013)

Add to Collection

Article Oncology

First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas

Jonathan R. Strosberg et al.

CANCER (2011)

Add to Collection

Article Medicine, General & Internal

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.

Eric Raymond et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Letter Biochemical Research Methods

A method and server for predicting damaging missense mutations

Ivan A. Adzhubei et al.

NATURE METHODS (2010)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Oncology

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Oncology

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

Sara Ekeblad et al.

CLINICAL CANCER RESEARCH (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.